{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:11:19Z","timestamp":1760076679502,"version":"build-2065373602"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Psoriasis and hidradenitis suppurativa are chronic inflammatory skin diseases with common pathogenesis, such as the involvement of IL-17A, which also plays an essential role in the development and metastasis of colorectal cancer. Xeligekimab, a novel IL-17A inhibitor, offers a targeted therapeutic approach for these conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 43-year-old male presented with a 12-year history of plaque psoriasis and hidradenitis suppurativa. Previous treatment with topical corticosteroids, Calcipotriol Betamethasone Ointment and acitretin provided poor control of psoriasis, resulting in significant quality-of-life impairment. His comorbidities include chronic hepatitis B managed with 10-year antiviral therapy and metastatic colorectal cancer treated with synchronous resection of liver metastases during primary tumor surgery 6 years ago (no recurrence).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 28 weeks of xeligekimab treatment, the patient experienced significant improvement in symptoms and skin lesions. The evaluation indicators demonstrated a sustained decline: PASI decreased from 51 to 0.8, BSA from 87% to 6%, DLQI from 20 to 1, and Hurley staging improved to Grade I. During follow-up, imaging and tumor marker testing revealed no signs of tumor and hepatitis B progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Xeligekimab demonstrated significant efficacy and acceptable safety over 28 weeks in this complex case of psoriasis with concurrent hidradenitis suppurativa, chronic hepatitis B, and metastatic colorectal cancer. Extended follow-up is ongoing to evaluate long-term outcomes, while larger prospective studies are warranted to validate biologic therapy for such multimorbid presentations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1651568","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:28:28Z","timestamp":1760074108000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A case report of plaque psoriasis comorbid with hidradenitis suppurativa, hepatitis B, and colorectal cancer treated with xeligekimab"],"prefix":"10.3389","volume":"16","author":[{"given":"Jun","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binbin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lunfei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1573715","article-title":"Targeting nail psoriasis: IL-17A inhibitors demonstrate site-specific superiority over IL-23 inhibitor in a 24-week dermoscopy-guided real-world cohort","volume":"16","author":"Yan","year":"2025","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis suppurativa: advances in diagnosis and treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"Jama"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12885-017-3210-z","article-title":"A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen","volume":"17","author":"Lereclus","year":"2017","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0001-7310(14)70017-1","article-title":"Role of IL-17 and IL-22 in autoimmunity and cancer","author":"Blake","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110757","article-title":"IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment","volume":"123","author":"Song","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1970706","article-title":"Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden","volume":"33","author":"Mastorino","year":"2022","journal-title":"J Dermatol Treat"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: A review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00797-9","article-title":"Secukinumab in patients with psoriasis and a personal history of Malignancy: A multicenter real-life observational study","volume":"12","author":"Pellegrini","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19328","article-title":"Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study","volume":"37","author":"Kridin","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13129","article-title":"The risk of Malignancy or progression of existing Malignancy in patients with psoriasis treated with biologics: case report and review of the literature","volume":"55","author":"Patel","year":"2016","journal-title":"Int J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.IJDVL_455_18","article-title":"Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series","volume":"87","author":"Yen","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/09546634.2018.1543843","article-title":"Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies","volume":"29","author":"Lasagni","year":"2018","journal-title":"J Dermatol Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S499039","article-title":"Successful treatment of linear psoriasis with the IL-17a-antagonist ixekizumab: A case report","volume":"15","author":"Christov","year":"2025","journal-title":"Psoriasis (Auckl)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13052-024-01835-2","article-title":"Ixekizumab as a successful treatment in pediatric generalized pustular psoriasis","volume":"51","author":"Esposito","year":"2025","journal-title":"Ital J Pediatr"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2474495","article-title":"Successful treatment of generalized pustular psoriasis during pregnancy with secukinumab in a patient hypersensitive to spesolimab: a case report","volume":"36","author":"Zhang","year":"2025","journal-title":"J Dermatol Treat"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.08.027","article-title":"A case of secukinumab-induced psoriasis in a 25-year-old man with improved hidradenitis suppurativa","volume":"53","author":"Yousefian","year":"2024","journal-title":"Jaad Case Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e70152","DOI":"10.1111\/liv.70152","article-title":"The relationship between TNF-alpha inhibitor potency and HBV reactivation in patients with rheumatic disorders","volume":"45","author":"Kuo","year":"2025","journal-title":"Liver Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae062","article-title":"A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis","volume":"191","author":"Cai","year":"2024","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e13550","DOI":"10.1111\/srt.13550","article-title":"Use of biologics in patients with psoriasis - A retrospective analysis based on real-world data","volume":"30","author":"Pan","year":"2024","journal-title":"Skin Res Technol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001163","article-title":"Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis","volume":"133","author":"Cai","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103818","article-title":"The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials","volume":"24","author":"Heidari","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/1203475418814234","article-title":"Comparison of management guidelines for moderate-to-severe plaque psoriasis: A review of phototherapy, systemic therapies, and biologic agents","volume":"23","author":"Ighani","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/biomedicines10061303","article-title":"Biologics and small molecule inhibitors for treating hidradenitis suppurativa: A systematic review and meta-analysis","volume":"10","author":"Huang","year":"2022","journal-title":"Biomedicines"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1651568\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:28:29Z","timestamp":1760074109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1651568\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2025.1651568"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1651568","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"article-number":"1651568"}}